OWLT.NYSEOwlet, INC

8-K: Owlet Reports Record Q2 Revenue, Profitability Boost

Sentiment:

Quarterly Results


Owlet, Inc. announced record second quarter 2026 revenue of $33.9 million, a 29.9% increase year-over-year, alongside significant improvements in gross margin and Adjusted EBITDA.

Better than expectedRevenue exceeded expectations with a 29.9% year-over-year increase, reaching a record $33.9 million.Subscription revenue showed exceptional growth, increasing by $2.4 million year-over-year.Gross margin improved significantly, both on a GAAP basis and when adjusted for one-time impacts.Net loss saw a dramatic reduction, and Adjusted EBITDA turned strongly positive, exceeding prior year performance and guidance expectations, especially when considering the impact of the tariff refund.

Summary

  • Owlet, Inc. reported record second quarter 2026 revenue of $33.9 million, a 29.9% increase from $26.1 million in Q2 2025.
  • Subscription revenue also reached a record high of $3.2 million, up from $0.9 million in Q2 2025.
  • GAAP gross margin was 64.4%, or 54.0% excluding a $3.5 million tariff refund impact, an improvement of 270 basis points year-over-year.
  • Net loss for the quarter was $0.6 million, a significant improvement from a $37.4 million net loss in Q2 2025. Excluding the $3.75 million tariff refund impact, the net loss was $4.4 million.
  • Adjusted EBITDA (non-GAAP) was $6.7 million, or $2.9 million excluding the tariff refund impact, compared to $0.5 million in Q2 2025.
  • The company updated its full-year 2026 financial outlook, maintaining revenue guidance and increasing gross margin and Adjusted EBITDA expectations, partly due to the tariff refund.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive report, with strong revenue growth and significant improvements in profitability metrics, particularly when excluding one-time tariff refund impacts.

Positives

  • Record Q2 revenue of $33.9 million, up 29.9% from Q2 2025.
  • Record Q2 subscription revenue of $3.2 million, a substantial increase from $0.9 million in Q2 2025.
  • Improved GAAP gross margin to 64.4% (54.0% excluding tariff refund impact), up 270 basis points year-over-year.
  • Significant reduction in net loss to $0.6 million from $37.4 million in the prior year's quarter.
  • Record Q2 Adjusted EBITDA of $6.7 million (or $2.9 million excluding tariff refund impact), a strong increase from $0.5 million in Q2 2025.
  • Updated full-year 2026 guidance shows increased expectations for Gross Margin (53%-55%) and Adjusted EBITDA ($10.75-$12.75 million).

Negatives

  • Operating expenses increased to $20.1 million from $15.1 million in Q2 2025, primarily due to higher marketing spend and severance costs.
  • The company identified errors impacting historical financial statements related to stock-based compensation valuation, requiring revisions to prior periods, though deemed not material to previously issued statements individually or in aggregate, but material to the three-month period ended March 31, 2026.

Risks

  • Commercial success of products and subscription services, and the ability to scale them.
  • Regulatory pathways for products, including FDA and international approvals, and maintaining certifications.
  • Competition and the ability to profitably manage growth.
  • Ability to successfully develop, launch, and scale new products and services, including AI-enabled offerings.
  • Need for additional financing and risks associated with debt agreements and covenants.
  • Ability to implement strategic initiatives, reduce costs, and innovate.
  • Protection of intellectual property and data privacy.
  • Impact of economic conditions, global events, and supply chain disruptions.

Future Outlook

The updated full-year 2026 financial outlook maintains total revenue guidance at $118-$122 million. Gross Margin is now expected to be between 53%-55% (up from 50%-52%), and Adjusted EBITDA is projected to be between $10.75-$12.75 million (up from $7-$9 million). These increases are attributed to the one-time tariff refund recognized in Q2 2026.

Management Comments

  • "Owlet delivered an exceptional second quarter, with record quarterly revenue, gross profit, and adjusted EBITDA," said Kurt Workman, Owlets President, Chief Executive Officer, and Co-Founder.
  • "We are executing across each of our strategic growth areas, and it is showing up in our results strong topline growth, standout international momentum, and continued Owlet360 subscription platform growth."
  • "We believe our biggest opportunity from here is growing subscribers, and that is exactly where the company is focused."
  • "We believe our competitive position has never been stronger. We have the first and only FDA-cleared baby monitor on the market, and we set another record for market share in the quarter."
  • "Our strategy from here is straightforward: firmly position Owlet as a data and services platform through subscription, win approximately one million new customers per year, and keep those families with us for at least two years."

Industry Context

StockSavvy.ai notes that Owlet's performance aligns with a growing trend in the health-tech and connected home device market, where recurring subscription revenue is increasingly crucial for sustainable growth and valuation. The company's focus on an FDA-cleared product positions it uniquely in the infant monitoring space, differentiating it from general consumer electronics.

Comparison to Industry Standards

  • The reported Q2 2026 revenue growth of 29.9% is strong compared to many established consumer electronics companies, but may be more in line with growth rates seen in emerging health-tech or SaaS businesses.
  • The increase in subscription revenue to $3.2 million, representing approximately 9.4% of total Q2 revenue, indicates a positive shift towards a more recurring revenue model, a standard for high-growth tech companies.
  • The gross margin of 54.0% (excluding tariff impact) is competitive for hardware-centric businesses with a software/service component, though direct comparisons are difficult without knowing specific product costs and pricing strategies of competitors like Nanit or Hatch.
  • The improvement in Adjusted EBITDA, turning positive and growing significantly, is a key indicator of operational leverage, a benchmark investors look for in scaling companies.

Legal Proceedings

  • The company faces risks related to regulatory pathways for its products, including submissions to, actions by, and decisions from regulators like the FDA and international equivalents.

Stakeholder Impact

  • Shareholders: Improved financial performance and updated positive outlook may lead to increased investor confidence and potential stock price appreciation.
  • Customers: Continued product innovation and focus on subscription services could offer enhanced value and insights into child well-being.
  • Employees: Increased marketing spend and operational focus may lead to growth opportunities, but also potential restructuring costs mentioned.

Next Steps

  • Continue to focus on growing subscribers through the Owlet360 platform.
  • Win approximately one million new customers per year.
  • Retain customers for at least two years to build a durable, higher-value business.
  • Expand opportunities in pediatric telehealth.
  • Scale internationally.
  • File Form 10-Q for the quarterly period ended June 30, 2026, by August 14, 2026, including revised financial statements.

Key Dates

DateDescription
August 11, 2026Date of Report (Earliest event reported)
June 30, 2026End of second quarter for financial reporting
August 11, 2026Date of press release reporting Q2 2026 financial results and business update
August 11, 2026Date of conference call to review results and provide business update
August 14, 2026Expected filing date for Form 10-Q for the quarterly period ended June 30, 2026, including revised financial statements

Recommendation

hold

The company demonstrated strong operational improvements and record results, with significant growth in revenue and a substantial reduction in net loss. The updated guidance is positive. However, the reliance on one-time tariff refunds to boost margins and EBITDA, coupled with ongoing risks related to competition, regulatory approvals, and the need for future financing, suggests a 'hold' rating until sustained profitability and growth without such one-off benefits are clearly established.

Keywords

infant monitoring, smart baby monitor, pediatric health, subscription revenue, FDA-cleared, financial results, Adjusted EBITDA, gross margin

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.